IMR Press / FBE / Volume 3 / Issue 2 / DOI: 10.2741/E265

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article

Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy

Show Less
1 Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
2 Department of Medicine, University Hospitals Case Medical Center, Cleveland, OH
3 Department of Medicine, Cleveland Clinic Foundation, Cleveland, OH
4 The Cleveland Cord Blood Center, Cleveland OH
5 University of Virginia, Charlottesville, VA
6 Department of Medicine, The Ohio State University Medical Center Hospital, Columbus, OH

*Author to whom correspondence should be addressed,

Academic Editor: Hiranmoy Das

Front. Biosci. (Elite Ed) 2011, 3(2), 506–514; https://doi.org/10.2741/E265
Published: 1 January 2011
(This article belongs to the Special Issue Stem cells in clinical medicine)
Abstract

The Phase I clinical study was designed to assess the safety and feasibility of a dose escalating intracoronary infusion of autologous bone marrow (BM)-derived CD133+ stem cell therapy to the patients with chronic total occlusion (CTO) and ischemia. Nine patients were received CD133+ cells into epicardial vessels supplying collateral flow to areas of viable ischemic myocardium in the distribution of the CTO. There were no major adverse cardiac events (MACE), revascularization, re-admission to the hospital secondary to angina, or acute myocardial infarction (AMI) for the 24-month period following cellular infusion. In addition, there were no periprocedural infusion-related complications including malignant arrhythmias, loss of normal coronary blood flow or acute neurologic events. Cardiac enzymes were negative in all patients. There was an improvement in the degree of ischemic myocardium, which was accompanied by a trend towards reduction in anginal symptoms. Intracoronary infusion of autologous CD133+ marrow-derived cells is safe and feasible. Cellular therapy with CD133+ cells to reduce anginal symptoms and to improve ischemia in patients with CTO awaits clinical investigation in Phase II/III trials.

Keywords
Safety
Efficacy
Autologous
Bone marrow
CD133
Chronic
Myocardial
Ischemia
Therapy
Share
Back to top